CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Search

We found 7294 result(s)

Saxagliptin + metformin (Komboglyze)

Last Updated: June 6, 2013
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Saxagliptin + metformin
Indications: Diabetes Mellitus, Type 2

  • Brand Name: Komboglyze
  • Manufacturer: Bristol-Myers Squibb / AstraZeneca Canada Inc.
  • Project Number: SR0336-000
  • Project Status: Withdrawn
  • Submission Type: Initial

Rotigotine (Neupro)

Last Updated: July 31, 2013
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Rotigotine
Indications: Parkinson’s Disease

  • Brand Name: Neupro
  • Manufacturer: UCB Canada Inc.
  • Project Number: SR0344-000
  • Project Status: Complete
  • Submission Type: Initial

Riociguat (Adempas)

Last Updated: September 30, 2013
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Riociguat
Indications: Pulmonary hypertension, chronic thromboembolic

  • Brand Name: Adempas
  • Manufacturer: Bayer Inc.
  • Project Number: SR0353-000
  • Project Status: Complete
  • Submission Type: Initial

Sofosbuvir (Sovaldi)

Last Updated: October 1, 2013
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Sofosbuvir
Indications: Hepatitis C, chronic

  • Brand Name: Sovaldi
  • Manufacturer: Gilead Sciences Canada Inc.
  • Project Number: SR0356-000
  • Project Status: Complete
  • Submission Type: Initial

Mirabegron (Myrbetriq)

Last Updated: November 27, 2013
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Mirabegron
Indications: Bladder, overactive

  • Brand Name: Myrbetriq
  • Manufacturer: Astellas Pharma Canada Inc.
  • Project Number: SR0363-000
  • Project Status: Complete
  • Submission Type: Initial

Macitentan (Opsumit)

Last Updated: December 16, 2013
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Macitentan
Indications: Pulmonary arterial hypertension

  • Brand Name: Opsumit
  • Manufacturer: Actelion Pharmaceuticals Canada Inc.
  • Project Number: SR0364-000
  • Project Status: Complete
  • Submission Type: Initial

Umeclidinium/vilanterol (Anoro Ellipta)

Last Updated: February 26, 2014
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Umeclidinium/vilanterol
Indications: Chronic Obstructive Pulmonary Disease

  • Brand Name: Anoro Ellipta
  • Manufacturer: GlaxoSmithKline Inc.
  • Project Number: SR0371-000
  • Project Status: Complete
  • Submission Type: Initial

Darunavir / cobicistat (TBC)

Last Updated: April 4, 2014
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Darunavir / cobicistat
Indications: HIV infection

  • Brand Name: TBC
  • Manufacturer: Janssen Inc.
  • Project Number: SR0378-000
  • Project Status: Withdrawn
  • Submission Type: Initial

Infliximab (Remsima)

Last Updated: May 30, 2014
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Infliximab
Indications: Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis

  • Brand Name: Remsima
  • Manufacturer: Fresenius Kabi Canada
  • Project Number: SE0383-000
  • Project Status: Withdrawn
  • Submission Type: Initial

Rifaximin (Zaxine)

Last Updated: August 5, 2014
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Rifaximin
Indications: Encephalopathy, Hepatic

  • Brand Name: Zaxine
  • Manufacturer: Salix Pharmaceuticals Inc.
  • Project Number: SR0388-000
  • Project Status: Complete
  • Submission Type: Initial